End-of-Life Treatment and Antibiotic Resistance Data Raise Questions
To the Editor:
I read with interest the recent article in CHEST by Levin and colleagues (September 2010), 1 which reported that only a limitation-of-therapy order in ICU patients was independently associated with acquisition of resistant organisms, whereas other factors such as antibiotic days, ICU length of stay prior to isolation of a resistant organism, antibiotic therapy prior to ICU admission, and so forth were not. However, the data reported and the study design raise some questions. Table 1 .
Second, also in 2007, Levin et al 3 published data on the same Israeli medical-surgical ICU, describing transmission of Acinetobacter baumannii due to the contamination of portable radiographs. One might speculate whether the high amount of A baumannii isolates present (94 within 6 months in the Israeli ICU vs only eight within 12 months in the Canadian ICU) was also because of a prolonged outbreak.
Third, in 450 patients, 649 unique pathogens were isolated, with a maximum of 331 being resistant.
1 Twenty-seven patients were excluded because they were infected or colonized at admission, and 82 were grouped as having a resistant pathogen, meaning that on average, a patient harbored four resistant pathogens, which seems fairly high.
Fourth, it remains unclear why data from incomparable ICUs (with respect to their attitude toward limitation of therapy, general resistance situation, amount of antibiotics used, etc) are combined to perform a logistic regression analysis (which requires homogeneity) to fi nd predictors for the isolation of resistant pathogens. Why was this not done separately for each ICU?
Finally, the authors concluded that nonwithdrawal of therapy leads to increased use of antibiotics and consecutively to a higher prevalence of resistant pathogens. However, another explanation might be that no more or less microbiologic sampling was done in 
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To the Editor:
We are complimented by Dr Meyers' interest in our publications 1 -3 and appreciate her comments. Dr Meyer comments on differences in isolate counts in our various publications. Careful examination of the methodology of the articles reveals that the Infection Control Hospital Epidemiology article included isolates resistant only to ciprofl oxacin, whereas the CHEST article included isolates resistant to all fl uoroquinolones. Unique isolates were defi ned as patient-, site-, and resistancepattern-specifi c, meaning that a patient who was heavily colonized with Pseudomonas aeruginosa , for example, could harbor isolates in the surgical wound, sputum, urine, blood, and surveillance cultures (fi ve isolates in this example of only one bacterial species). Further, even a single change in antibiotic sensitivity could double the number of unique isolates. This may have somewhat artifi cially infl ated the number of resistant isolates reported.
For these reasons, counting isolates has signifi cant limitations, and thus, the current research focused on patient acquisition of resistant bacteria, regardless of the site or the number of isolates involved. Considering patient acquisition of resistant organisms is, in our opinion, more clinically relevant and robust. When considered in this way, the number of patients acquiring ciprofl oxacinresistant bacteria in the Infection Control Hospital Epidemiology and CHEST reports is identical. Indeed, isolate distribution was included in the current study only to illustrate the huge differences in the load of resistant bacteria that existed between the Jerusalem and Toronto ICUs.
The high number of Acinetobacter baumanni isolates in Jerusalem may well have resulted from a very prolonged outbreak. However, we would suggest that the conditions in the Jerusalem ICU (whether related to end-of-life care decisions or not) contributed to the maintenance of the outbreak and further justifi ed the comparison of the two ICUs.
As reported in the "Discussion" section of the article, combining the two populations (from Jerusalem and Toronto) is problematic. Although it is true that the populations are not identical, there is much in common between them. Further, performing separate regression analyses is limited because in the Toronto environment of low prevalence of resistant bacteria, few patients will acquire these bacteria, regardless of any other care consideration.
Regarding the fi fth point, this is our hypothesis. Patients usually die within hours of withdrawal of therapy, so clearly there is limited opportunity for additional microbiologic studies or administration of antibiotics. In contrast, patients who die without withdrawal of therapy are obviously severely ill, are at high risk of infection, and receive more antibiotics. They are also present in the ICU for longer periods of time and can therefore act as a reservoir for resistant bacteria for the rest of the ICU.
To discover whether there really is a connection between endof-life care and the acquisition of resistant bacteria will require a multicenter prospective study. We are currently planning such a study, to be performed during the coming winter under the aegis of the European Society of Intensive Care, and would welcome Dr Meyers' support and participation. 
